ABSTRACT
Acinctobacter species are common non fermentative gram negative bacilli isolated in clinical laboratory most frequently encountered species. Acinetobacter resistance is develop due to acquired resistance. Because of frequent multidrug resistance isolates carbapenems have become important for treating resistant strains. There is a need for rapid screening & detection of MBL in Acinetobacter to modify the treatment. The present study was aim to determine the resistance of A.baumanii complese to various classes of drugs and to carbapenems and MBL production. Samples such as urine, blood, sputum, pus & body fluids. All samples were processed as per CLSI guidelines. Meropenem resistant strains were screened for carbapenemase and MBL production. Out of 92 Acinetobacter 85 (92.39%) were Acinetobacter baumanii. More than 80% resistance is seen in 3rd generation Cephalosporins. Out of 21 meropenem resistant strains 14 were carbapenemase positive and 3 were MBL producers. Our study shows raising trend of multidrug resistance and carbapenem. This will help in early detection and better treatment modalities. Abbreviations: MRSA–Methicillin resistant Staphylococcus aureus, ESBL – Extended sputum β - lactamases GNB – Gram negative bacilli, MDR – Multi drug resistance